What AbbVie’s Oxford R&D Expansion Means for UK Pharma

US pharmaceutical giant AbbVie is expanding its R&D presence in Oxford as part of more than £120m (US$161m) invested and committed to the UK’s life sciences sector.

At the centre of the expansion is a new 12,000-square-foot facility designed to strengthen AbbVie’s research capabilities across three key therapeutic areas: immunology, neuroscience and oncology. 

The expansion builds on AbbVie’s existing presence in Oxford, established through its October 2022 acquisition of Oxford-founded biotechnology company DJS Antibodies. 

Beyond the new facility, the wider investment encompasses scientific research, academic collaborations and talent development, reflecting a broader commitment to the UK's life sciences ecosystem.

Kelly Sanderson Schrems, UK Vice President and General Manager at AbbVie, describes the facility as a “proud moment” for the firm's UK division in a LinkedIn post.

She writes: “AbbVie Oxford combines the agility and entrepreneurial spirit of biotech with the scale and expertise of our worldwide R&D network.

“I’ve been fortunate to see the expertise and commitment behind this expansion first-hand. It’s a testament to all the colleagues who have helped make it happen.”

AbbVie employs more than 1,100 people across its UK sites in Oxford, Maidenhead and Marlow. The Oxford expansion will increase its research capabilities in the region, while strengthening the company's connections with the academic and clinical expertise concentrated in the area.

The UK’s 'Golden Triangle'

Oxford makes up one-third of the UK's 'Golden Triangle' of life sciences, alongside London and Cambridge. 

The region boasts a glut of leading universities, hospitals, pharmaceutical companies and biotechnology businesses, creating an environment in which scientific research can be translated into clinical applications and potential new medicines.

AbbVie is not alone in recognising the opportunities presented by this ecosystem. Other pharmaceutical heavyweights, including AstraZeneca and GSK, are also investing in their UK research infrastructure.

AstraZeneca, for example, has its global headquarters and flagship Discovery Centre (DISC) on the Cambridge Biomedical Campus. The facility supports drug discovery and development across the company's therapeutic areas, employing more than 2,000 scientists.

In April 2026, AstraZeneca announced that it would resume a £300m (US$403m) UK investment programme after previously pausing its Cambridge expansion. 

The commitment includes completing the £200m (US$269m) Rosalind Franklin building at its Cambridge site, alongside investment in a new laboratory at its Macclesfield facility to advance data-driven drug development.

GSK has also announced plans to establish a new £400m (US$538m) global R&D centre on the Cambridge Biomedical Campus. The 300,000-square-foot facility will become home to more than 1,000 scientists, with a phased relocation of employees from its existing Stevenage research site planned by 2029.

The campus itself is home to more than 470 life sciences, biotechnology and AI companies, with over 22,000 people working across the wider research and healthcare community.

More than one million patients are treated there each year, providing opportunities to connect scientific discovery with clinical practice.

For AbbVie, access to this concentration of research and clinical expertise is an important part of its Oxford strategy.

“AbbVie Oxford is expanding to further harness the leading life sciences ecosystem in Oxford that brings together academic and clinical expertise and strong scientific talent,” says Jon Sedgwick, Senior Vice President and Global Head of Discovery Research at AbbVie.

“Human biology and reverse translation are fundamental to our approach for identifying promising disease targets and combination therapies to advance potential new medicines for people living with serious diseases where significant unmet needs remain.”

The investment comes against a backdrop of renewed efforts by the UK Government to improve the country's attractiveness to pharmaceutical investors. 

The UK-US pharmaceutical arrangement, finalised in April 2026, introduced commitments around medicines spending, pricing and market access, with the aim of improving the operating environment for pharmaceutical companies.

AbbVie’s academic commitments

Alongside expanding its physical research infrastructure, AbbVie is seeking to deepen its relationships with the universities and research organisations that underpin the UK's scientific capabilities.

The company supports and engages with more than 100 universities and research organisations each year in the UK, helping to advance scientific research and develop opportunities for future innovation.

Its collaboration with the University of Oxford is one example. The partnership is exploring how patients with certain inflammatory conditions respond to different treatments, examining both molecular and clinical outcomes across an extended period of their disease course.

By developing a better understanding of these responses, the research could help inform the development of future medicines and support more targeted approaches to treating inflammatory diseases.

AbbVie also funds a postdoctoral research programme at the University of Oxford, investigating the biological drivers of several inflammatory conditions.

AbbVie - key partners

Genmab

CEO: Jan van de Winkel | HQ: Copenhagen, Denmark

Genmab is a Danish biotechnology company specialising in antibody therapeutics and the development of innovative treatments for cancer and other serious diseases. Its longstanding partnership with AbbVie has focused on oncology, including the development of epcoritamab, marketed as Epkinly in the US. The collaboration combines Genmab's antibody technology with AbbVie's global development and commercial capabilities.

Iambic Therapeutics

CEO: Tom Miller | HQ: San Diego, California

Iambic is a clinical-stage biotechnology and technology company using AI to accelerate drug discovery and development. Announced in September 2026, its multi-year collaboration with AbbVie will apply its molecular superintelligence platform to small-molecule drug discovery across immunology, neuroscience and oncology. The partnership combines Iambic's AI capabilities with AbbVie's therapeutic expertise to identify potential new medicines.